Streetbeat News

Stock Prices

VKTX

Market whales have shown a bullish stance on Viking Therapeutics (NASDAQ:VKTX) with 71% of recent options trades being bullish. The options activity suggests a price target range of $35 to $100. Despite a recent 3.4% price drop, analysts have set high price targets, with some downgrades noted.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 4:15 pm

LLY

NVO

PFE

VKTX

Viking Therapeutics (NASDAQ:VKTX) is set to report its Q3 earnings, with its stock up 240% YTD due to excitement around its weight-loss drug VK2735. The drug aims to outperform competitors like Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Investors are eager for updates on Viking's drug pipeline and FDA discussions.

Portfolio Pulse from Surbhi Jain

October 22, 2024 | 4:14 pm

AMID

HELX

MEDP

Medpace Holdings, Inc. (NASDAQ:MEDP) shares fell after Q3 results showed revenue below expectations and a lowered FY24 revenue forecast. Despite a rise in EBITDA and cash reserves, concerns over weak net bookings and elevated cancellations contributed to the decline. Analyst Max Smock suggests potential buying opportunities if gross bookings stabilize.

Portfolio Pulse from Lekha Gupta

October 22, 2024 | 4:07 pm

NDRA

ENDRA Life Sciences (NASDAQ:NDRA) shares surged by 94.6% after announcing a post-market clinical study of its TAEUS liver system at LMU University Hospital in Munich. The study aims to compare TAEUS' liver fat measurement capabilities with the MRI-PDFF test, potentially enhancing its clinical data portfolio and supporting its FDA De Novo submission by mid-2025.

Portfolio Pulse from Henry Khederian

October 22, 2024 | 4:05 pm

ANF

Former Abercrombie & Fitch CEO Michael Jeffries has been arrested in a federal sex trafficking investigation. The case involves allegations of exploiting young men, with accusations tied to Abercrombie & Fitch's operations. The company's stock has seen a slight decline following the news.

Portfolio Pulse from Erica Kollmann

October 22, 2024 | 4:05 pm

COTY

FXI

ULTA

L'Oreal reports that the Chinese market has become more challenging, impacting its sales performance. This could have implications for other beauty and cosmetics companies operating in China.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 4:05 pm

COTY

ULTA

L'Oréal reported Q3 net sales of €10.28 billion, missing the estimated €10.52 billion. Organic sales growth was 3.4%, below the expected 6.0%. This underperformance may impact competitors like Coty, Estée Lauder, and Ulta Beauty.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 4:04 pm

NEP

NextEra Energy Partners (NYSE:NEP) is set to announce its quarterly earnings on October 23, 2024, with an expected EPS of $0.55. Despite past EPS beats, the stock has seen price declines, and analysts currently rate it as 'Underperform' with a potential downside. The company's strong revenue growth and efficient use of equity are positive, but profitability lags behind peers.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 4:03 pm

EGP

EastGroup Props (NYSE:EGP) is set to release its quarterly earnings on October 23, 2024, with analysts expecting an EPS of $2.10. The company's past performance shows mixed results, with a recent EPS beat leading to a share price drop. Analysts have a Neutral consensus rating for EGP, with a 10.26% potential upside based on the average price target. The company shows strong revenue growth and profitability metrics compared to peers.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 4:03 pm

TMUS

T-Mobile US is set to release its quarterly earnings on October 23, 2024, with analysts expecting an EPS of $2.43. The company's previous earnings beat expectations, leading to a share price increase. Analysts rate T-Mobile US as 'Outperform' with a price target of $222.81. The company shows strong financial performance with high revenue growth and profitability metrics.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 4:03 pm